Literature DB >> 28920463

Evaluation of genotoxicity and subchronic toxicity of standardized rose hip extract.

A Nagatomo1, M Oguri1, N Nishida1, M Ogawa2, A Ichikawa2, Y Tanaka-Azuma1.   

Abstract

Rose hip is the fruit of the rose plant, which is widely used in food, cosmetics and as a traditional medicine. Therefore, rose hip is considered safe and has a sufficient history of consumption as food. However, few studies have reported on the safety of rose hip extracts in toxicological analyses. Thus, to evaluate the safety of rosehip polyphenol MJ (RHPMJ), an aqueous ethanol extract standardized with the trans-tiliroside content, we performed genotoxicity and 90-day repeated oral dose toxicity studies in compliance with the Organisation for Economic Co-operation and Development-Good Laboratory Practice. RHPMJ did not induce gene mutations in reverse mutation tests of Salmonella typhimurium TA98, TA100, TA1535, TA1537 and Escherichia coli WP2 uvrA strains and did not induce chromosomal aberrations in cultured Chinese hamster lung (CHL/IU) cells. Moreover, micronucleus tests using rat bone marrow showed RHPMJ had no micronucleus-inducing potential. Finally, 90-day repeated oral dose toxicity studies (100-1000 mg/kg) in male and female rats showed no treatment-related toxicity in rats. These data indicate that the RHPMJ had no genotoxicity and a no-observed-adverse-effect level greater than 1000 mg/kg in rats.

Entities:  

Keywords:  Rose hip; chromosome aberrations; genotoxicity; micronucleus; rats; safety; subchronic toxicity; trans-tiliroside

Mesh:

Substances:

Year:  2017        PMID: 28920463     DOI: 10.1177/0960327117730881

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  1 in total

1.  The effects of Rosa foetida extract along with self-care education on primary dysmenorrhea: study protocol for a randomized clinical trial.

Authors:  Fatemeh Shabani; Shabnam Omidvar; Parvin Sajadi Kaboudi; Hajar Pasha; Soraya Khafri; Hossein Najafzadehvarzi; Fatemeh Nasiri Amiri; Mahbobeh Faramarzi; Zinatossadat Bouzari
Journal:  Trials       Date:  2022-08-09       Impact factor: 2.728

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.